New hope for tough breast cancers: 3-Drug combo tested before surgery
NCT ID NCT02593175
Summary
This study tested whether adding a targeted drug (panitumumab) to two standard chemotherapy drugs could shrink tumors before surgery in patients with triple-negative breast cancer. The treatment was specifically for patients whose cancer didn't respond well to initial chemotherapy. Researchers gave the three-drug combination to 43 patients before surgery to see if it could eliminate cancer cells in the breast and lymph nodes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIA BREAST CANCER AJCC V6 AND V7 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.